Oxytocin

Synthetic oxytocin is an FDA-approved obstetric hormone (e.g., Pitocin) for medically indicated labor induction/augmentation and for postpartum uterine contraction and hemorrhage control - not an approved wellness, bonding, or weight-loss peptide.

A cyclic nonapeptide identical to endogenous oxytocin; marketed synthetic injectable products include Pitocin (oxytocin injection, USP) [R1].

Pitocin and equivalent oxytocin injection products are FDA-approved prescription drugs. Labeled antepartum uses include initiating or improving uterine contractions where medically indicated, and adjunctive use in incomplete or inevitable abortion; postpartum uses include producing uterine contraction during the third stage of labor and controlling postpartum bleeding or hemorrhage. Elective labor induction without a medical indication is not a labeled use [R1]. Non-obstetric "wellness," intranasal bonding, or gray-market research uses are not FDA-approved indications for these products.

• Decades of obstetric use under labeled indications; modern systematic reviews continue to evaluate oxytocin strategies around active labor and postpartum hemorrhage prevention/treatment in clinical settings [R2].
• Efficacy and safety outside labeled obstetric contexts (e.g., social cognition, autism, weight, athletic recovery) are not established by the FDA-approved labeling for Pitocin-class products [R1].

Extensive neuroendocrine literature on oxytocin pathways exists; animal and experimental findings are not a substitute for labeled human obstetric indications.

Labeled risks include uterine hyperstimulation, fetal distress, water intoxication with prolonged IV infusion, and other obstetric complications requiring monitored administration [R1]. Unregulated intranasal or injectable "research oxytocin" has unverified identity, purity, and sterility.

No change to the core FDA obstetric indication set identified for this update. Separately marketed research peptides are unrelated to approved Pitocin supply chains.